Kronos Bio (NASDAQ:KRON) Stock Price Up 1.1%

Kronos Bio, Inc. (NASDAQ:KRON) shares shot up 1.1% during mid-day trading on Wednesday . The company traded as high as $1.00 and last traded at $0.96. 883,997 shares traded hands during mid-day trading, an increase of 192% from the average session volume of 302,912 shares. The stock had previously closed at $0.95.

Kronos Bio Trading Up 2.0 %

The stock’s 50-day moving average is $1.14 and its 200-day moving average is $1.12. The stock has a market cap of $60.10 million, a P/E ratio of -0.51 and a beta of 1.82.

Kronos Bio (NASDAQ:KRON) last announced its earnings results on Thursday, March 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.08. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $1.50 million. Kronos Bio had a negative net margin of 1,791.87% and a negative return on equity of 58.79%. On average, equities analysts forecast that Kronos Bio, Inc. will post -1.74 EPS for the current year.

Hedge Funds Weigh In On Kronos Bio

Several large investors have recently made changes to their positions in the business. Cerity Partners LLC bought a new position in shares of Kronos Bio during the 4th quarter valued at about $513,000. Acuta Capital Partners LLC boosted its position in shares of Kronos Bio by 128.2% during the 3rd quarter. Acuta Capital Partners LLC now owns 718,739 shares of the company’s stock valued at $934,000 after purchasing an additional 403,739 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Kronos Bio by 6.4% during the 3rd quarter. Acadian Asset Management LLC now owns 614,945 shares of the company’s stock valued at $798,000 after purchasing an additional 36,909 shares in the last quarter. Institutional investors own 64.09% of the company’s stock.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.